Navigation Links
Anti-inflammatory drugs (coxibs) interfere with aspirin's clotting ability -- Ben-Gurion U.
Date:12/23/2009

BEER-SHEVA, ISRAEL -- December 23, 2009 -- A new study conducted at Ben-Gurion University of the Negev (BGU) reveals that Celebrex and other anti-inflammatory coxib medications may counter the positive effects of aspirin in preventing blood clots.

The research, published in the Proceedings of the National Academy of Sciences (PNAS), indicates that people who are taking aspirin and coxibs together are in fact inhibiting the aspirin's effectiveness in preventing heart attacks and strokes.

"This finding strongly suggests that humans who are consuming coxibs and a low dose of aspirin simultaneously are exposed to a greater risk of cardiovascular events," said Professor Gilad Rimon, Department of Clinical Pharmacology, Ben-Gurion University of the Negev in Israel.

In the past decade, a new group of anti-inflammatory drugs, coxibs, which include Celebrex and Arcoxia was developed to treat arthritis as well as other pain. Arthritis patients who take Celebrex are instructed to take low-dose aspirin to counteract Celebrex's own potential clot-promoting effect.

Aspirin is the oldest and one of the most effective non steroidal anti-inflammatory drugs. It is also well known for its ability to prevent the blood clots that can potentially lead to heart attack and stroke. Therefore, doctors often advise patients who are more prone to heart-related illnesses to take a daily tablet of low dose aspirin (81 mg). Approximately, 50 million Americans take aspirin every day to reduce their risk of cardiovascular diseases.

Now, the BGU research suggests that in the presence of coxibs, asprin's protective role in preventing new blood clots is blunted.

This finding mirrors a cooperative study conducted at the University of Michigan, Ann Arbor that showed for the first time that Celebrex and other coxibs directly interfere with the protective qualities of aspirin.


'/>"/>

Contact: andrew lavin
andrewlavin@alavin.com
516-944-4486
American Associates, Ben-Gurion University of the Negev
Source:Eurekalert

Page: 1

Related biology news :

1. Anti-inflammatory drug blocks brain plaques
2. The quest for specific anti-inflammatory treatment
3. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
4. Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs
5. Socioeconomic position associated with effectiveness of HIV drugs
6. Using green chemistry to deliver cutting-edge drugs
7. MIT model could improve some drugs effectiveness
8. Plants can be used to study how and why people respond differently to drugs
9. Insulins brain impact links drugs and diabetes
10. Scientists unveil structure of molecular target of many drugs
11. Market testing of dietary supplements and drugs underscores value of USPs public health programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/14/2016)... 14, 2016 http://www.apimages.com ) ... --> - Renvoi : image disponible via AP ... --> --> DERMALOG, le leader ... nouveaux lecteurs d,empreintes digitales pour l,enregistrement des réfugiés ... utilisé pour produire des cartes d,identité aux réfugiés. ...
(Date:3/10/2016)... BELL, Pa. , March 10, 2016   Unisys ... U.S. Customs and Border Protection (CBP) is testing its ... San Diego to help identify certain ... States . The test, designed to help determine the ... pedestrian environment, began in February and will run until May ...
(Date:3/8/2016)... March 8, 2016   Valencell , the ... announced it has secured $11M in Series D ... a new venture fund being launched by UAE-based ... from existing investors TDF Ventures and WSJ Joshua ... continue its triple-digit growth and accelerate its pioneering ...
Breaking Biology News(10 mins):
(Date:4/27/2016)... 2016 NanoStruck Technologies Inc. ... ( Frankfurt : 8NSK) gibt bekannt, ... 13. August 2015 die Genehmigung von der CNSX ... 200.000.000 Einheiten auf 400.000.000 Einheiten zu erhöhen, um ... wurden 157.900.000 Einheiten mit dem ersten Teil der ...
(Date:4/27/2016)... ... 2016 , ... NDA Partners Chairman Carl Peck, MD ... Consultant. Mr. Clark was formerly a Vice President with US Pharmacopeia, where ... monographs based on analytical methods. NDA Partners Expert Consultants are top tier ...
(Date:4/27/2016)... ... April 27, 2016 , ... Global Stem Cells Group CEO Benito ... the founder of GSCG affiliate Kimera Labs in Miami. , In 2004, Ross received ... cell transplantation for hematologic disorders and the suppression of graft vs. host disease (GVHD) ...
(Date:4/27/2016)... , April 27, 2016 ... research report with specific focus on US, EU, ... Japan , to the healthcare business intelligence ... library. Complete report on the Flow ... companies and supported with 282 tables and figures ...
Breaking Biology Technology: